

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 July 2019 (04.07.2019)



(10) International Publication Number
WO 2019/129397 A1

(51) International Patent Classification:

A61K 9/14 (2006.01) A61P 25/24 (2006.01)
A61K 31/135 (2006.01)

(21) International Application Number:

PCT/EP2018/076394

(22) International Filing Date:

28 September 2018 (28.09.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17461651.6 29 December 2017 (29.12.2017) EP

(71) Applicant: **CELON PHARMA S.A.** [PL/PL]; ul. Ogrodowa 2A, 05-092 Kielpin (PL).

(72) Inventors: **WIECZOREK, Maciej**; ul. Majowa 20, 05-092 Kielpin (PL). **TRATKIEWICZ, Ewa**; ul. Spiewakow 20/2, 03-029 Warszawa (PL). **PERKO, Przemyslaw**; ul. Lagowska 3/47, 01-464 Warszawa (PL).

(74) Agent: **SITKOWSKA, Jadwiga**; Al. Komisji Edukacji Narodowej 83/106, 02-777 Warszawa (PL).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: DRY POWDER KETAMINE COMPOSITION FOR USE IN THE TREATMENT OF DEPRESSION BY PULMONARY ADMINISTRATION

(57) Abstract: A dry powder inhalable pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression by administration via pulmonary route. The composition is especially useful for the treatment of treatment-resistant or treatment-refractory depression.



WO 2019/129397 A1

DRY POWDER KETAMINE COMPOSITION FOR USE IN THE TREATMENT OF DEPRESSION BY PULMONARY ADMINISTRATION

5 Technical field

The present invention relates to a composition comprising ketamine, in particular dry powder formulation for use in a method of treatment of depression by pulmonary administration.

Prior art

10 Depression, especially major depressive disorder, bipolar disorder and treatment-resistant depression (TRD) is a serious problem in a modern society. Many treatment options have been developed for treating depression, including monotherapy or combination therapy in a convenient for patients oral administration regimen. However, there is a relatively high percentage of patients
15 that are treatment-refractory or partially or totally treatment-resistant to existing antidepressants. In practice, at present the only real choice in such severe cases can be electroshocks.

Ketamine is a known anesthetic and analgetic, used for anesthesia and in the treatment of chronic pain. Ketamine is a chiral compound and can exist as a
20 racemate and as S-enantiomer (known as esketamine) or R-enantiomer (known as arketamine). Ketamine can form a pharmaceutically acceptable salts and in pharmaceutical applications is generally used as preferred hydrochloride salt. The optical rotation of an enantiomer varies between ketamine and its salts. For example, while esketamine free base is dextrarotatory S-(+), esketamine
25 hydrochloride is levorotatory S-(-).

Since about one decade antidepressant activity of ketamine and its S-isomer (esketamine) is explored, especially in the treatment of treatment-resistant or treatment refractory depression (G. Serafini et al., The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review., Current
30 Neuropharmacology, 2014, 12, 444-461). Treatment-resistant depression is a term used in clinical psychiatry to describe cases of major depressive disorder that

do not respond adequately to appropriate courses of at least two antidepressants in a suitable dose for a suitable time.

Data collected up to now show exceptional properties of ketamine and esketamine. The effect is very quick (after 2-3 hours from administration) and relatively long-
5 lasting – a few days after single dose of a medicament. The rapidity of the clinical effect is surprisingly high and unexpected, since the effect of antidepressants present on the market appears after at least two weeks, even three to four weeks of day-to-day administration. Therefore, ketamine or esketamine could be used as
10 a drug of first choice in patients with major depression with enhanced suicide risk that are resistant to existing oral antidepressants. The scale of the effect is also very high; about 2/3 of the patients with treatment-resistant depression is responsive to ketamine treatment.

The knowledge of the pharmacology of ketamine is still poor. As a dissociative anesthetic, the drug may exert dissociative and psychomimetic effects (DP).
15 Available data show that this effects are correlated with systemic concentration of the drug. Dissociative and psychomimetic effects are among most often observed side-effects and significantly lower the comfort of patients. However, there are still groups of patients that respond to the treatment with ketamine without experiencing DP effects. Hence, still exists a therapeutic window, although narrow,
20 for effective and safe use of ketamine in the treatment of depression without DP.

Ketamine undergoes extensive first-pass metabolism effect in the liver. Primarily, norketamine is produced as the initial metabolite. Norketamine is then metabolized to further metabolites. The knowledge about norketamine and further metabolites is still not full. On the level of action on NMDA receptor norketamine is many times
25 less active than ketamine. Other metabolites are also mostly less active than ketamine. Furthermore, little is known about toxicity of norketamine and other metabolites. This, in combination with high individual variations of their concentrations dependent on the status of hepatic enzymes, as a rule makes them undesired compounds. There are also reports on correlation of some hydroxylated
30 metabolites of ketamine with psychotic and dissociative symptoms.

In previous studies ketamine and esketamine were administered in the treatment of depression intravenously or intranasally. Attempts of oral administration were

generally unsuccessful or the effects were observed only after several weeks of administration.

Literature describes many examples of ketamine pharmacokinetics depending on the administration route.

5 Administration route with currently expected minimum level of metabolites is an intravenous one. After intravenous infusion of racemic ketamine at 0.5 mg/kg for 40 minutes, the parent drug maintains its systemic concentration about 200 ng/ml for about 40 minutes, afterwards the concentration falls down quickly with a half-period below 2 hours. Simultaneously, norketamine reaches its maximum
10 concentration at the level of 10-20% of ketamine concentration. The percentage of area-under-curve (AUC) norketamine to ketamine is about 20-40%.

Oral administration is the administration route, after which maximum concentration of metabolites is expected. However, after oral administration the drug rapidly undergoes metabolism to norketamine. Norketamine level is equal to 500-1000%
15 of ketamine level. Area-under-curve (AUC) for norketamine is even higher, exceeding 1000%.

The bioavailability of orally administered ketamine is very low (ca. 16-20%); while intravenous administration results in marked increase in ketamine bioavailability, it has also many disadvantages (e.g. long-time of infusion, patient discomfort, need
20 for surveillance).

US2007/0287753A1 discloses the use of ketamine for treating treatment-resistant or refractory depression. The only formulation tested is the intravenous infusion, and transdermal administration is contemplated as well. Intranasal administration is only generally described, including intranasal administration of a dry powder
25 aerosol formulation comprising finely divided powder of ketamine, a dispersant and bulking agent. However, with intranasal administration ketamine to oropharyngeal area significant amounts of ketamine will be swallowed by a patient by oral route and can undergo systemic metabolism to norketamine to cause undesired side effects.

DE102007009888 discloses the use of S-ketamine in the treatment of depression, in the dosage of 0.3 to 1.0 mg/kg. Although all possible administration routes are generally mentioned, the only formulation tested is intravenous infusion, mentioned as the preferred one.

- 5 WO2013/138322 discloses the use of esketamine in the treatment of treatment-refractory or treatment-resistant depression. Test for efficacy of esketamine was described in prophetic example with esketamine intravenous infusion.

WO2014/143646 and WO2014/152196 disclose pharmaceutical composition of esketamine in the form of the aqueous formulation of esketamine hydrochloride, preferably for nasal administration, for use in the treatment of treatment-refractory or treatment-resistant depression.

Mucoadhesive oral forms of esketamine and pharmacokinetics of esketamine after oral, intranasal and intravenous administration are described in WO2014/020155.

15 K. Jonkman et al., *Anesthesiology* 127 (4), 675-683, 10, 2017, studied on healthy volunteers the safety and feasibility of delivery of ketamine by inhalation of nebulized esketamine hydrochloride saline solution as a new route of ketamine administration. It has been found that inhaled ketamine bioavailability was reduced due to both dose-independent and dose-dependent impairment of pulmonary uptake. This was related to the high viscosity of esketamine; the viscosity of esketamine is three to four times greater than that of water. Because of this the administration via nebulization will be imprecise and non-reliable.

20 Singh et al., *Biological Psychiatry* 80:424-413, 2016, observed a rapid onset of robust antidepressant effects in patients with treatment resistant depression (TRD) after a 40-minute i.v. infusion of either 0.20 mg/kg or 0.40 mg/kg of esketamine. The lower dose may allow for better tolerability while maintaining efficacy.

25 The above illustrates the absolute medical need and importance of development of high-dose ketamine formulation that is both highly effective as well as convenient and easy to everyday self-administration by the patient including self-administration on out-patient basis to ensure high patient compliance. Such a formulation should first of all deliver therapeutic ketamine dose to the blood, should

be characterized with high effectiveness, including rapid therapeutic effect and low risk of undesired effects, such as DP, due to precise dosing. Such a formulation should allow only a minimum level of systemic first-pass metabolites such as norketamine and hydroxylated metabolites, especially assure acceptable (es)ketamine to (es)norketamine ratio, both in view of avoiding reduction of ketamine level actually administered and unwanted metabolites effects.

The target was to achieve similar ketamine plasma concentration and hence similar antidepressant effect as that by Sing et al. with intravenous infusion of 0.20 mg/kg lasting 40 minutes using route of administration more convenient for a patient and producing less adverse effects.

The above problems have been solved by the present invention that provides a high-dose and stable dry powder ketamine pharmaceutical composition for use in a method of treatment of depression by pulmonary administration route in a reliable, reproducible and convenient manner.

15 Summary of the invention

The invention provides a dry powder pharmaceutical composition comprising ketamine or a pharmaceutically acceptable salt thereof as a medicine for use in a method of treatment of depression by pulmonary administration.

In another aspect, the invention provides ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression, wherein ketamine or its pharmaceutically acceptable salt is administered by pulmonary route as a dry powder pharmaceutical formulation.

In another aspect, the invention provides a method of treatment depression in a subject in need thereof, wherein ketamine or its pharmaceutically acceptable salt is administered to a subject by pulmonary route as a dry powder pharmaceutical formulation.

The invention will be described in more detail below, with reference to the drawing, wherein:

Figure 1 presents NGI deposition data for the composition of Example 1;

- Figure 2 presents NGI deposition data for the composition of Example 2;
Figure 3 presents NGI deposition data for the composition of Example 3;
Figure 4 presents NGI deposition data for the composition of Example 4;
Figure 5 presents NGI deposition data for the composition of Example 5;
5 Figure 6 presents NGI deposition data for the composition of Example 6;
Figure 7 shows esketamine plasma concentration vs time after administration of various single doses of dry powder composition of Example 2;
Figure 8 shows esketamine plasma concentration vs time after administration of a sequence of single doses of dry powder composition of Example 2; and
10 Figure 9 presents adverse effect distribution after administration of dry powder composition of Example 2.

Detailed description of the invention

The object of the invention is a dry powder pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt as a medicine for use in a method
15 of treatment of depression by pulmonary administration, i.e. administration via pulmonary route.

Another object of the invention is ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression, wherein ketamine or its pharmaceutically acceptable salt is administered by pulmonary route as a dry
20 powder pharmaceutical formulation.

Another object of the invention is a method of treatment of depression in a subject in thereof, wherein ketamine or its pharmaceutically acceptable salt is administered to a subject by pulmonary route as a dry powder pharmaceutical formulation.

25 Preferably, in the use according to the invention, esketamine, especially esketamine hydrochloride, is self-administered pulmonary by a patient by inhalation of a dry powder esketamine composition or formulation in a sequence of administrations consisting of multiple single doses (inhalation events), such as

at least 3 single doses, each inhalation event consisting of multiple puffs, such as 1, 2, 3 or 4 puffs, preferably in 3 or 4 puffs, said sequences being separated from each other by a break period without any inhalation (rest period). Preferably, such as sequence lasts at least 30 minutes, for example lasts 30 minutes, and includes
5 3 sequences of administration and break periods between are preferably equal, i.e. are 15 minutes break (rest) period.

Preferably, in the use according to the invention, esketamine, especially esketamine hydrochloride, is self-administered pulmonary by a patient by inhalation of a dry powder esketamine composition or formulation in a sequence
10 lasting 30 minutes consisting of 3 single doses (inhalation events), each inhalation event consisting of 3 or 4 puffs, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation. Such a composition or formulation is described in Example 2 below. Between such each inhalation event (single dose) there is provided a break period without any
15 inhalation, preferably there are two equal breaks lasting about 15 minutes, i.e. first single dose is administered at time 0, second single dose is administered after about 15 minutes and the third single dose is administered at 30 minute. Such a sequence allows to obtain plasma concentration profile that provides plasma concentration infusion at the level having antidepressant effect, as known from
20 prior art tests of intravenous infusions.

According to the invention, the term "ketamine" encompasses racemic ketamine and its enantiomers esketamine and arketamine, both as a free base and pharmaceutically acceptable salts thereof.

In a preferred embodiment ketamine is esketamine.

25 In another embodiment, ketamine is racemic ketamine.

Preferred pharmaceutically acceptable ketamine salt is hydrochloride.

In a most preferred embodiment, the composition of the invention comprises esketamine hydrochloride.

In another embodiment, the composition of the invention comprises racemic
30 ketamine hydrochloride.

Preferably, in the use according to the invention, ketamine, especially esketamine such as esketamine hydrochloride, is self-administered pulmonary by a patient by inhalation of a dry powder ketamine composition or formulation in a sequence of administrations consisting of multiple single doses (inhalation events), such as at least 3 single doses, each single dose or inhalation event consisting of multiple puffs, such as 1, 2, 3 or 4 puffs, preferably in 3 or 4 puffs, said sequences being separated from each other by a break period without any inhalation (rest period). Preferably, such as sequence lasts at least 30 minutes, for example lasts 30 minutes, and includes 3 sequences of administration and break periods between are preferably equal, i.e. are 15 minutes break (rest) period.

Preferably, in the use according to the invention, esketamine such as esketamine hydrochloride, is self-administered pulmonary by a patient by inhalation of a dry powder esketamine composition or formulation in a sequence lasting 30 minutes consisting of 3 single doses (inhalation events), each inhalation event consisting of 3 or 4 puffs, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation. Such a composition or formulation is described in Example 2 below. Between such each inhalation event (single dose) there is provided a break period without any inhalation, preferably there are two equal breaks lasting about 15 minutes, i.e. first single dose is administered at time 0, second single dose is administered after about 15 minutes and the third single dose is administered at 30 minute. Such a sequence allows to obtain plasma concentration profile that provides plasma concentration infusion at the level having antidepressant effect, as known from prior art tests of intravenous infusions.

The term "medicine" as used herein can be used interchangeably with the term "medicinal product". It should be understood that "medicine" and "medicinal product" have essentially the same meaning in terms of the invention.

The term "treatment-resistant or treatment refractory depression" (TRD) is well known in the art and means depression in patients not responding to at least two prior attempts of adequate antidepressive treatment using commonly known antidepressant therapies. The term is generally described for example in US8,785,500 and US2015/0056308.

The term “bipolar disorder” is well known in the art and means a disorder that causes periods of depression and periods of abnormally elevated mood.

The term “major depression” is well known in the art and means a disorder characterized by at least two weeks of low mood that is present across most
5 situations.

In one aspect the composition of the invention comprises from 2 mg to 100 mg of ketamine calculated as a free base per nominal unit dose.

In a particular embodiment, the composition of the invention comprises from 2 mg to 60 mg of ketamine, especially 2 mg to 40 mg of ketamine, such as from 3 mg to
10 15 mg of ketamine, calculated as a free base, per nominal unit dose.

In another embodiment, the composition of the invention comprises further one or more additives selected from the group consisting of a carbohydrate bulking agent in the amount of 30 to 95% by weight and a stabilizing agent in the amount of 0.2 – 3% by weight, with respect to the total weight of the composition.

15 The composition comprises ketamine, especially esketamine hydrochloride, having median particle diameter d_{50} of 1 – 10 μm , such as 1 – 8 μm , especially 3 μm , d_{10} of 0.2 – 5 μm and d_{90} of 3 – 35 μm .

Median particle size d_{50} is a parameter obtained by laser diffraction technique with dry dispersion using Sympatec HELOS laser diffractometer attached with
20 ASPIROS feeder. For measurement, raw ketamine, especially esketamine hydrochloride, is dispersed with pressure 3.0 bar in total amount of 30 mg per sample.

The composition is a dry powder formulation for administration using dry powder inhalers. Conventional and typical dry powder inhalers can be used for this
25 purpose.

The term “dry powder” is known for a skilled person and should be understood in a manner conventional in the art as a solid mix of particles that is fluidized when the patient inhales after actuation of the inhaler device.

The term “nominal unit dose” in accordance with the invention relates to the
30 ketamine dose as present (loaded) in the composition that is destined for a single

administration. The nominal unit dose can be a measured dose of the dry powder to be ready for the patient to take, contained in a single unit, such as a capsule or single compartment in a blister, or a dose to be taken from for delivery from the multi-dose dry powder reservoir.

- 5 The term “emitted dose” relates to the proportion of the nominal unit dose that exits/leaves the device after inhalation by a patient.

The dry powder pharmaceutical composition or formulation for use according to the invention may comprise further pharmaceutical excipients, i.e. one or more additives selected from the group consisting of a carbohydrate bulking agent (a carrier) in the amount of 30 to 95% by weight and a stabilizing agent in the amount
10 of 0.2 – 3% by weight, with respect to the total weight of the composition.

Suitable carbohydrate bulking agent (a carrier) can be lactose, D-mannitol, glucose monohydrate, trehalose, especially trehalose dihydrate, erythritol, dextrose, maltose, sorbitol or xylitol. Especially convenient bulking agent is milled lactose,
15 such as lactose monohydrate or anhydrous lactose, especially lactose monohydrate, having suitable granulometry. Suitable granulometry is defined as having d_{50} 30 – 200 μm (Sympatec HELOS) as the main coarse fraction (especially 80 μm). Examples of suitable lactose monohydrate commercial grades are Lactohale 200 (LH200), Lactohale 100 (LH100) and Lactohale 200LP. Various
20 types of inhalers may require appropriate selection of lactose grade most suitable for performance thereof. Such a selection is within common skills of a skilled person.

Typical amount of the bulking agent in the composition of the invention is 30 – 95% by weight, especially 30 to 80% by weight, with respect to the total weight of the
25 composition.

Pharmaceutical excipients/additives include also a stabilizer (also called force control agent – FCA), i.e. a substance that reduces adhesion and cohesion. Suitable stabilizers are for example magnesium stearate, lecithin, and aminoacids, such as leucine. Especially preferred stabilizer is magnesium stearate.

- 30 Stabilizer “disturbs” the weak binding forces between the small particles and thus helps to keep the particles separated, reduces self-adhesion of small particles and

also adherence to other particles in the formulation if such other particles are present, reduces the adhesion to the inner surfaces of the inhaler, as well as improves rheological properties of powder - powder flowability.

5 The amount of the stabilizer in the composition of the invention is 0.2 – 3% by weight, especially 0.8% by weight, with respect to the total weight of the composition.

Composition or formulation for use according to the invention is prepared by blending in a high-shear mixer a bulking agent/carrier of suitable granulometry with a stabilizer, and then adding ketamine, especially esketamine hydrochloride, of
10 suitable granulometry and again blending in a high-shear mixer.

Alternatively, ketamine, especially esketamine hydrochloride, of suitable granulometry is co-processed (blended) with a stabilizer in a high-shear mixer, and then the bulking agent/carrier is added and again mixed in a high-shear mixer.

The composition is a dry powder formulation for administration using dry powder
15 inhalers. Conventional and typical dry powder inhalers can be used for this purpose.

The formulation may be administered by three device categories: single-unit dose inhaler in which each dose, such as in a capsule, is loaded into the device before use; a multi-dose reservoir inhaler in which a bulk supply of dry powder with
20 plurality of doses is preloaded into the device; and a multi-unit dose inhaler in which a plurality of single doses are individually sealed in separate compartments such as in a blister cavity, and discharged each time the device is actuated. Preferred is the multi-unit dose inhaler in which a plurality of single doses are individually sealed, such as in the blister, and discharged each time the device is actuated.

25 In one embodiment of the use according to the invention as defined above, the medicine for administration via pulmonary route is a blister with plurality of individual nominal unit doses premetered and individually sealed. One preferred example of such an inhaler is Diskus type inhaler.

In another embodiment of the use according to the invention as defined above, the medicine for administration via pulmonary route is a capsule with a single nominal unit dose.

5 In another embodiment of the use according to the invention as defined above, the medicine for administration of a single dose via pulmonary route is a multi-dose powder reservoir.

The composition for use according to the invention provides emitted dose of at least 1.0 mg of ketamine calculated as a free base, corresponding to 1.2 mg of ketamine hydrochloride.

10 The composition for use according to the invention provides the fraction of the dose delivered locally directly to the lungs that is at least 40%, such as from 40 to 50%, especially 40% to 60%, especially up to 85%, of the emitted unit dose.

Emitted dose is the portion of nominal unit dose that is emitted from the inhaler device and leaves the inhaler device as an aerosol and hence is available to the
15 patient.

Only part of emitted dose reaches the lungs and thus circulating blood of a patient as the dose delivered to the lungs (also called Fine Particle Dose - FPD) or fraction delivered to the lungs (also called Fine Particle Fraction – FPF). Some part reaches gastrointestinal tract via oropharyngeal and oral routes, i.e. is swallowed, and is
20 accessible for undesired first-part metabolism.

It has been surprisingly found that in spite of well-known problems with inhalation dry powder formulation of high doses of an active substance for pulmonary administration, the uniform and stable high-dose ketamine, especially esketamine hydrochloride dry powder composition can be obtained that when administered by
25 pulmonary route provides therapeutic ketamine level in the circulating blood of a patient, i.e. at least 50 to 100 ng/ml, such as 70 to 100 ng/ml, such as 70-80 ng/ml, such as about 100 ng/ml. Therapeutic ketamine level relates to the level in the blood that is effective in the treatment of depression, especially major depressive disorder, such as treatment resistant or treatment-refractory depression, and may
30 be dependent on the subject, gender, age, severity of the disease, the type of the

inhaler, and may vary depending on whether ketamine is racemic ketamine or enantiomeric ketamine.

The fraction of the emitted dose delivered to the lungs is surprisingly high, in contrast with typical inhalation compositions wherein the standard is that only 15
5 to 20% of the emitted dose is delivered to the lungs.

The fraction of the emitted dose delivered locally directly to the lungs (also called Fine Particle Fraction – FPF) can be determined using well-known and conventional methods and assays. Such methods and assays include any of those described in European Pharmacopeia 9.0, Chapter 2.9.18, Preparations for
10 inhalation; Aerodynamic assessment of fine particles for determination of Fine Particle Dose. In particular, the Next Generation Pharmaceutical Impactor (NGI) (Ph. Eur. Apparatus E) can be used to assess and control the aerodynamic particle size distribution (APSD). The NGI apparatus is as presented in Figs 2.9.18.-12 and 2.9.18.-13 on page 333 of European Pharmacopeia 9.0.

15 Emitted dose and fine particle dose and fraction (FPF and FPD) are strongly dependent on two factors i.e. on the formulation and on the device. For the device the most discriminatory factor for emitted dose is resistance. The resistance of a dry powder inhaler (DPI) is an intrinsic value which depends on the design of the inhalation channel, the metering cup and the air inlets. DPIs can be classified into
20 four resistance groups (low, medium, medium-high, high) with respect to the inhalation flow required to produce a pressure drop of 4 kPa. This value was chosen because it is the one recommended by pharmacopoeia for the in vitro characterization of the dose emitted from a DPI. Additionally for capsule-based DPIs can be limited by the powder retention in the capsule and device, which lead
25 to reduction in the emitted dose.

Emitted dose testing is relatively straightforward. The device is ‘fired’ into a sampling apparatus that enables the capture of the measured dose on a filter. The aerodynamic particle size distribution of inhaled products is measured using the technique of multistage cascade impaction, here Next Generation Impactor (NGI).
30 The collected quantity of active ingredient is determined further by HPLC analysis. The inhalers are tested at a predetermined flow rate, and the pressure drop across the inhaler is 4.0 kPa in line with the Ph Eur.

Efficient particle capture is ensured by coating the particle collection surface of each of stages 1-7, as well as the MOC and the pre-separator base, with a coating substance. The central cup of the pre-separator is filled with adequate diluent.

After discharging the powder to the NGI (Number of actuations per impactor $n=1$ for one analysis) by opening the two-way solenoid valve for the required time at flow control which generate pressure drop across the inhaler 4 kPa the following operations are performed:

I. Stages 1 to 7 and MOC. Each stage is washed with appropriate diluent (extraction of drug substance). NGI tray loaded with the cups on a Copley Gentle Rocker is gently shaken for 10 minutes.

II. Mouthpiece adapter. Deposited inhalation powder on adapter is rinsed with appropriate diluent a volumetric flask and sonicated for 10 minutes.

III. Induction port. Deposited inhalation powder from induction port is rinsed with appropriate diluent into a volumetric flask and sonicated for 10 minutes.

IV. Preseparator. Deposited inhalation powder from these component is rinsed with appropriate diluent into a volumetric flask and sonicated for 10 minutes.

Finally collected samples from each stage of impactor are filtered analyzed by high-performance liquid chromatography

Composition of for use according to the invention has an appropriate ketamine, in particular esketamine hydrochloride pharmacokinetics profile that enables achievement of approximately 50 to 100 ng/ml of the ketamine plasma concentration over 40 minutes after pulmonary administration directly to the lungs by inhalation. Said plasma concentration corresponds to antidepressive effect. Maintaining this concentration over time mimics 40-minute intravenous infusion known to be effective in depression and well-tolerated.

The present invention will now be with reference to the accompanying examples, which are not intended to be limiting.

Examples

General manufacturing procedure:

A sum of lactose monohydrate and magnesium stearate are sieved through 0.25 mm mesh and mixed in high-shear mixer for 3 minutes. Obtained mixture is sieved with active substance through 0.5 mm mesh and mixed in high-shear mixer for 5 minutes.

To eliminate electrostatic charges, antistatic PE bags are used during the process.

Vacuum filling process (blisters):

Vacuum-drum technology dose forming process is used for blister filling. The
 5 blister cavity is in volume range of 15 to 45 mm³ (especially ca. 30 mm³). Powder
 which is filled into cavity is in amount of 10 – 30 mg (especially 23 mg).

During process parameters of vacuum-drum device are:

Vacuum pressure: -0 – 500 mBar, especially 50 – 400 mBar

Fluidization pressure: - 0.1 - -0.4 Bar

10 Fluidization time: 50 – 2000 ms, especially 50 -300 ms

Filling time: 50 – 700 ms, especially 50 – 400 ms

Sealing time: 100 – 600ms

Sealing tests of filled blisters are performed under vacuum.

Finally, the blister strips are coiled into the medical device.

15 **Filling process (capsules):**

Capsules to be filled are placed in the sockets closed ends down. Powder is
 discharged from the dosator and comes directly to the capsules. The powder with
 which the capsules are to be filled is placed in the dosator, may be tamped and
 discharged into the capsules.

20 During the process parameters of capsule filling device are:

Rotation: 1- 70 rpm

Tamping high: 1 – 10mm

Dosator high: 1 – 250mm

Finally, the filled capsules are mounted into the medical device.

25

Ketamine dry inhalation powder for blisters and capsules

The following compositions has been prepared in accordance with the above
 general procedure in the scale of 0.9 kg.

Example 1

30 Component	Amount (mg/unit)
Esketamine hydrochloride	3.45 (corresponds to 2.99 mg esketamine)
Lactose monohydrate LH200 LP	19.16
Magnesium stearate	0.39

Example 2

5	Component	Amount (mg/unit)
	Esketamine hydrochloride	4.61 (corresponds to 4 mg esketamine)
	Lactose monohydrate LH200 LP	18.20
	Magnesium stearate	0.18

Example 3

10	Component	Amount (mg/unit)
	Esketamine hydrochloride	5.06 (corresponds to 4.39 mg esketamine)
	Lactose monohydrate LH200 LP	17.581
	Magnesium stearate	0.359

The compositions have been found uniform in accordance with requirements of
 15 Ph.Eur.2.9.40. Average esketamine hydrochloride content (n=10) was in the range
 92.5% - 107.5% of nominal dose.

The process has been found scalable to the scale of 1.8 kg.

Aerodynamic Particle Size Distribution (APSD) test of the compositions of the
 Examples 1, 2 and 3 of the invention.

20 The compositions of Examples 1, 2 and 3 of the invention have been tested using
 the Next Generation Pharmaceutical Impactor (NGI) (Ph. Eur. Apparatus E) in
 accordance with the procedure for powder inhalers.

The results of the tests are presented in Table 1 below and in Figure 1 (Example
 1), Figure 2 (Example 2) and Figure 3 (Example 3) of the drawing, wherein upper
 25 diagrams present APSD data for the whole NGI and bottom diagrams present
 APSD data for stages 1-7 and MOC. The following abbreviations are used for the
 results of the tests:

MA – mouth adapter

T- induction port

30 PS – Pre-separator

S1-S7 – stages of NGI

MOC – micro-orifice collector

ISM – Impactor sized mass; mass entering the impactor excluding non-sizing portions

MMAD (μm) – mass median aerodynamic diameter. Defined as the diameter at which 50% of the particles by mass are larger and 50% are smaller.

GSD – geometric standard deviation. Measure of the spread of an aerodynamic particle size distribution

FPF – fine particle fraction (%)

FPD – fine particle dose

10 Table 1. NGI deposition data

Example No	1	2	3
MA [mg]	0.043	0.194	0.074
T	0.166	0.713	0.740
PS	0.598	0.262	0.825
S1	0.063	0.157	0.179
S2	0.193	0.599	0.541
S3	0.308	0.538	0.588
S4	0.243	0.392	0.345
S5	0.112	0.201	0.179
S6	0.061	0.121	0.105
S7	0.048	0.087	0.070
MOC	0.037	0.054	0.054
ISM (mg)	1.00	1.99	1.88
Total Mass on Impactor (mg)	1.07	2.15	2.06
Total Mass on System (mg)	1.87	3.32	3.70
Mass on Impactor/Actuation (mg)	1.07	2.15	2.06
Mass on System/Actuation (mg)	1.87	3.32	3.70
FPD ≤ 5.0 mcm (mg) esketamine	1.0	1.7	1.6
FPF ≤ 5.0 mcm (%)	49.0	51.0	44.0
MMAD (mcm)	2.6	2.9	3.0
GSD	1.8	1.8	1.8

The obtained results showed a product with expected quality attributes.

The composition of the invention demonstrated appropriate homogeneity and a very high level of fine particle fractions, with:

15 FPF > 49%, FPD 1.0 mg; and emitted dose: 2.3 mg, for Example 1
 FPF > 47%, FPD: 1.7 mg; and emitted dose: 3.6 mg, for Example 2, and
 FPF > 44%, FPD: 1.6 mg; and emitted dose: 3.9 mg, for Example 3.

Esketamine dry inhalation powder for capsules

5 The following compositions has been prepared in accordance with the above general procedure in the scale of 0.9 kg.

Example 4

	Component	Amount (mg/unit)
	Esketamine hydrochloride	5.00 (corresponds to 4.34 mg esketamine)
10	Lactose monohydrate LH200 LP	19.8
	Magnesium stearate	0.2

Example 5

	Component	Amount (mg/unit)
	Esketamine hydrochloride	10.00 (corresponds to 8.67 mg
15	esketaamine)	
	Lactose monohydrate LH200 LP	39.6
	Magnesium stearate	0.4

Example 6

	Component	Amount (mg/unit)
20	Esketamine hydrochloride	20.00 (corresponds to 17.34mg
	esketaamine)	
	Lactose monohydrate LH200 LP	79.2
	Magnesium stearate	0.8

25 **Aerodynamic Particle Size Distribution (APSD)** test of the compositions of Examples 4, 5 and 6 of the invention.

The compositions of Examples 4, 5 and 6 of the invention have been tested using the Next Generation Pharmaceutical Impactor (NGI) (Ph. Eur. Apparatus E) in accordance with the procedure for powder inhalers.

30 The results of the tests are presented in Table 2 below and in Figures (Example 4), Figure 5 (Example 5) and Figure 6 (Example 6) of the drawing, wherein higher

diagrams present APSD data for the whole NGI and lower diagrams present APSD data stages 1-7 and MOC.

Table 2. NGI deposition data

Example No	4	5	6
MA [mg]	0.090	0.174	0.329
T	0.655	1.328	2.877
PS	0.262	0.774	1.838
S1	0.368	0.669	1.621
S2	0.915	1.505	3.293
S3	0.631	1.057	2.270
S4	0.449	0.705	1.386
S5	0.273	0.414	0.719
S6	0.167	0.300	0.505
S7	0.108	0.214	0.374
MOC	0.061	0.166	0.283
ISM (mg)	2.61	4.36	8.83
Total Mass on Impactor (mg)	2.97	5.03	10.45
Total Mass on System (mg)	3.98	7.30	15.49
Mass on Impactor/Actuation (mg)	2.97	5.03	10.45
Mass on System/Actuation (mg)	3.98	7.30	15.49
FPD \leq 5.0 mcm (mg) esketamine	2.4	3.9	7.9
FPF \leq 5.0 mcm (%)	59	54	51
MMAD (mcm)	3.0	3.0	3.2
GSD	1.9	1.9	2.6

5

The obtained results showed a product with expected quality attributes.

The invented formulation demonstrated appropriate homogeneity and a very high level of fine particle fractions, with:

FPF > 59%, FPD 2.4 mg; emitted dose: 4.2 mg, for Example 4

10 FPF > 54%, FPD: 3.9 mg; emitted dose: 7.1 mg, for Example 5, and

FPF > 51%, FPD: 7.9 mg; emitted dose: 16.5 mg, for Example 6.

The dry powder pharmaceutical composition of the invention provided emitted esketamine hydrochloride dose at the level up to 97%, such as up to 85% of the
 15 nominal dose and at least 40% of fine particle fraction (fraction delivered to the lungs) for emitted esketamine dose.

Example 7

Pharmacokinetics of inhaled esketamine dry powder in healthy volunteers

Esketamine hydrochloride dry powder formulation of Example 2 was administered to healthy volunteers pulmonary, i.e. directly to the lungs using dry powder inhaler (DPI) (by self-administration).

One puff of dry powder formulation contained 4.6 mg of esketamine hydrochloride, corresponding to 4 mg of esketamine free base and excipients 18.22 mg of lactose monohydrate and 0.18 mg of magnesium stearate.

A single dose was an inhalation events consisting of 1 to 6 puffs, i.e. 4 to 24 mg of esketamine free base nominal dose.

In part A of the study, designed as a one-centre single ascending dose, the medicine was delivered in a single dose once daily (up to 6 consecutive puffs) to 18 healthy volunteer subjects. Subjects were divided into 6 cohorts, cohorts receiving 1, 2, 3, 4, 5 or 6 puffs in a single doses (inhalation events), respectively.

Collection of blood samples for determination of esketamine and esnorketamine concentration and calculation of pharmacokinetic parameters was performed for up to 24 hours following the start of the test.

The aim of the study was to determine the amount of puffs needed to obtain plasma concentration similar to that sufficient to achieve antidepressant effect as for 0.20 mg/kg 40 minutes intravenous infusion. It can be predicted on the basis of literature data that this corresponds to concentration at 40 min of infusion between about 60 to 100 ng/ml. It was also the aim to determine the number of puffs that allow to avoid a sharp peak of plasma concentration that is considered an important factor inducing adverse psychomimetic and dissociative effects.

The results of the part A of the test are presented on Figure 7 that shows esketamine plasma concentration over time after administration of various single doses of dry powder composition of Example 2. As it can be seen, the number of puffs that allows to obtain plasma esketamine concentration sufficient for antidepressant effect and without sharp peak of said concentration was determined to be 1 to 4 puffs, corresponding to 4 to 16 mg of esketamine free base nominal dose.

Therefore, a single dose (inhalation event) consisting of 1 to 4 puffs was selected for the next Part B of the test.

In part B of the study the composition of Example 2 was administered to 12 healthy volunteer subjects divided into 4 cohorts in four different single doses each cohort (i.e. each single dose consisting of 1, 2, 3 or 4 puffs, respectively) in one day in the administration sequence consisting of three administrations of single dose
5 (inhalation event) in the period of 30 minutes, Between inhalation events there were 15 minutes break periods, i.e. first single dose was administered at 0 min., second single dose was administered at 15 min, and third single dose was administered at 30 min.

The aim of Part B was to investigate pharmacokinetic properties of esketamine
10 following different dosing schemes in healthy subjects and determine the scheme that enables achievement of the appropriate plasma concentration over time to mimic the 40-minute intravenous infusion (part B),

The results of the of the part B of the test are presented on Figure 8 that shows esketamine plasma concentration over time after administration of various single
15 doses of dry powder composition of Example 2 in a sequence of 3 administrations of single doses during 30 minutes. Figure 8 shows also (the area between two bold black lines) a simulation of esketamine plasma concentration after 0.2 mg/kg 40 minutes i.v. infusion.

As it can be seen form Fig. 8, sequence of administration of 3 single doses
20 consisting of 3 or 4 puffs allowed to obtain plasma concentration profile mimicking quite well esketamine intravenous infusion at the level corresponding to antidepressant effect.

Both in Part A and Part B of the study the adverse effects were monitored and assessed by a psychiatrist. The summary of the adverse effects is presented in
25 Fig. 9. As can be seen, no serious effects were observed, all adverse effects being assessed as mild, occasionally moderate. Psychomimetic effects were transient, lasting up to 30 minutes following administration. There were no discontinuations due to adverse effects or toxicity.

The above shows that pulmonary administration of esketamine, i.e. directly to the
30 lungs is a promising way of treating depression, in particular TRD, by convenient self-administration by a patient. Plasma concentration profile is quite smooth, consistent with a target profile and safe for chronic administration.

Claims

1. A dry powder pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression,
5 by direct administration to the lungs via pulmonary route.
2. Ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression, wherein ketamine or its pharmaceutically acceptable salt is administered by pulmonary route as a dry powder pharmaceutical composition.
3. The composition or ketamine for use according to claim 1 or 2 wherein
10 pharmaceutically acceptable salt is hydrochloride.
4. The composition or ketamine for use according to any one of claims 1 to 3 wherein ketamine is esketamine hydrochloride.
5. The composition or ketamine for use according to any one of claims 1 to 4,
15 wherein the composition comprises from 2 mg to 100 mg of micronized ketamine calculated as a free base per nominal unit dose.
6. The composition or ketamine for use according to claim 5, wherein composition comprises from 2 mg to 40 mg of micronized ketamine calculated as a free base per nominal unit dose.
7. The composition or ketamine for use according to claim 6, wherein the
20 composition comprises 4 mg of micronized esketamine calculated as a free base per nominal unit dose.
8. The composition or ketamine for use according to any one of claims 1 to 7, wherein composition comprises one or more additives selected from the group consisting of a carbohydrate bulking agent in the amount of 30 to 95% by weight
25 and a stabilizing agent in the amount of 0.2 – 3% by weight, with respect to the total weight of the composition.
9. The composition or ketamine for use according to any one of claims 1 to 8, wherein composition comprises ketamine having median particle diameter d₅₀ of 1 – 10 μm, d₁₀ of 0.2 – 5 μm and d₉₀ of 3 – 35 μm, as measured by laser
30 diffraction technique.

10. The composition or ketamine for use according to any one of claims 5 to 9, wherein the composition provides emitted dose of at least 1.0 mg of ketamine calculated as a free base, corresponding to 1.2 mg of ketamine hydrochloride.
11. The composition or ketamine for use according to claim 10, wherein the fraction
5 of the emitted dose delivered to the lungs is at least 40%.
12. The composition or ketamine for use according to any one of claims 1 to 11, wherein the composition for administration via pulmonary route is comprised in a blister with plurality of individual nominal unit doses premetered and individually sealed.
- 10 13. The composition or ketamine for use according to any one of claims 1 to 11, wherein the medicine for administration via pulmonary route is comprised in a capsule with a single nominal unit dose.
14. The composition or ketamine for use according to any one of claims 1 to 11, wherein the medicine for administration via pulmonary route is comprised in a
15 multi-dose powder reservoir.
15. The composition or ketamine for use according to any one of claims 1 to 14, wherein ketamine, preferably esketamine, is self-administered pulmonary by a patient by inhalation of a dry powder ketamine composition or formulation in a sequence of administrations consisting of multiple single doses, for example such
20 as a sequence of at least 3 single doses, each single dose consisting of multiple puffs, such as 1, 2, 3 or 4 puffs, preferably 3 or 4 puffs, said sequences being separated from each other by a break period without any inhalation.
16. The composition or ketamine for use according to claim 15, wherein the administration comprises the sequence of esketamine three single doses
25 consisting of 3 or 4 puffs in a period of 30 minutes, single doses being separated by a break periods of 15 minutes, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation.
17. A method of treatment of depression in a subject in thereof, wherein ketamine or its pharmaceutically acceptable salt is administered to a subject by pulmonary
30 route as a inhalable dry powder pharmaceutical formulation.

18. The method according to claim 16 wherein ketamine pharmaceutically acceptable salt is hydrochloride.
19. The method to claim 17 or 18 wherein ketamine is esketamine hydrochloride.
20. The method according to any one of claims 17 to 19, wherein the composition
5 comprises from 2 mg to 100 mg of micronized ketamine calculated as a free base per nominal unit dose.
21. The method according to claim 20, wherein composition comprises from 2 mg to 40 mg of micronized ketamine calculated as a free base per nominal unit dose.
22. The method according to claim 21, wherein the composition comprises 4 mg
10 of micronized esketamine calculated as a free base per nominal unit dose.
23. The method according to any one of claims 17 to 22, wherein composition comprises one or more additives selected from the group consisting of a carbohydrate bulking agent in the amount of 30 to 95% by weight and a stabilizing agent in the amount of 0.2 – 3% by weight, with respect to the total weight of the
15 composition.
24. The method according to any one of claims 17 to 23, wherein composition comprises ketamine having median particle diameter d50 of 1 – 10 μm , d10 of 0.2 – 5 μm and d90 of 3 – 35 μm , as measured by laser diffraction technique.
25. The method according to any one of claims 20 to 24, wherein the composition
20 provides emitted dose of at least 1.0 mg of ketamine calculated as a free base, corresponding to 1.2 mg of ketamine hydrochloride.
26. The method according to claim 25, wherein the fraction of the emitted dose delivered to the lungs is at least 40%.
27. The method according to any one of claims 17 to 26, wherein the composition
25 for administration via pulmonary route is comprised in a blister with plurality of individual nominal unit doses premetered and individually sealed.
28. The method according to any one of claims 17 to 26, wherein the medicine for administration via pulmonary route is comprised in a capsule with a single nominal unit dose.

29. The method according to any one of claims 1 to 26, wherein the medicine for administration via pulmonary route is comprised in a multi-dose powder reservoir.
30. The method according to any one of claims 1 to 29, wherein ketamine, preferably esketamine, is self-administered pulmonary by a patient by inhalation of
5 a dry powder ketamine composition or formulation in a sequence of administrations consisting of multiple single doses, for example such as a sequence of at least 3 single doses, each single dose consisting of multiple puffs, such as 1, 2, 3 or 4 puffs, preferably 3 or 4 puffs, said sequences being separated from each other by a break period without any inhalation.
- 10 31. The method according to claim 30, wherein the administration comprises three esketamine single doses consisting of 3 or 4 puffs in a period of 30 minutes, single doses being separated by a break periods of 15 minutes, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation.

15





Fig. 1





Fig. 2





Fig. 3





Fig. 4




Fig. 5





Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2018/076394

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K9/14 A61K31/135 A61P25/24
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61K A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2007/287753 A1 (CHARNEY DENNIS S [US] ET AL) 13 December 2007 (2007-12-13) cited in the application	1,2,17
Y	paragraph [0063] paragraph [0081] - paragraph [0094]	1-31
X	WO 96/25925 A1 (WEG STUART L [US]) 29 August 1996 (1996-08-29)	1,2
Y	page 14, lines 1-12 ----- -/--	1-31

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 19 November 2018	Date of mailing of the international search report 07/12/2018
--	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Sindel, Ulrike
--	---

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2018/076394

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>KELLY JONKMAN ET AL: "Pharmacokinetics and Bioavailability of Inhaled Esketamine in Healthy Volunteers :", ANESTHESIOLOGY., vol. 127, no. 4, 1 October 2017 (2017-10-01), pages 675-683, XP055460101, PHILADELPHIA, PA, US ISSN: 0003-3022, DOI: 10.1097/ALN.0000000000001798 the whole document</p>	1-31
A	<p>----- US 2013/236573 A1 (SINGH JASKARAN [US] ET AL) 12 September 2013 (2013-09-12) paragraph [0057] -----</p>	1-31
A	<p>----- WO 2014/020155 A1 (CLINPHARM REFORM GMBH [DE]) 6 February 2014 (2014-02-06) cited in the application example 11 page 15, line 30 - line 33 -----</p>	1-31

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2018/076394

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 2007287753	A1	13-12-2007	AU 2007229866 A1	04-10-2007
			CN 101466364 A	24-06-2009
			EP 2012762 A2	14-01-2009
			JP 2009530385 A	27-08-2009
			KR 20090029690 A	23-03-2009
			US 2007287753 A1	13-12-2007
			US 2014256821 A1	11-09-2014
			US 2015056308 A1	26-02-2015
			US 2017151191 A1	01-06-2017
			US 2017181966 A1	29-06-2017
			WO 2007111880 A2	04-10-2007

WO 9625925	A1	29-08-1996	AT 245024 T	15-08-2003
			AU 733284 B2	10-05-2001
			CA 2213567 A1	29-08-1996
			DE 69629108 D1	21-08-2003
			DE 69629108 T2	22-04-2004
			DK 0814790 T3	10-11-2003
			EP 0814790 A1	07-01-1998
			ES 2205018 T3	01-05-2004
			JP 4173538 B2	29-10-2008
			JP H11500729 A	19-01-1999
			WO 9625925 A1	29-08-1996

US 2013236573	A1	12-09-2013	CL 2014002406 A1	09-01-2015
			CN 104519878 A	15-04-2015
			CO 7071129 A2	30-09-2014
			CR 20140410 A	17-11-2014
			GT 201400191 A	03-07-2017
			HK 1209323 A1	01-04-2016
			KR 20140136982 A	01-12-2014
			PE 19062014 A1	05-12-2014
			PH 12014501997 A1	24-11-2014
			SG 11201405530S A	27-11-2014
			US 2013236573 A1	12-09-2013
US 2014093592 A1	03-04-2014			
WO 2013138322 A1	19-09-2013			

WO 2014020155	A1	06-02-2014	US 2014079740 A1	20-03-2014
			WO 2014020155 A1	06-02-2014
